Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report
Chao Sun(Second Hospital of Shandong University), Kewei Ma(Jilin University), Ye Guo(Jilin University), Peng Zhang(Tongji University), Xu Wang(Anhui Medical University), Shi Qiu(Hainan Medical University), Zhiguang Yang(Jilin University), Guoguang Shao(First Hospital of Jilin University), Yunpeng Liu(Shenyang Institute of Automation), Yinghui Xu(University of Utah)
Cited by 4
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508